GT Biopharma Q2 FY26 net loss narrows to $4.5 million; operating loss widens to $4.5 million
Reuters2026/08/14 12:03- GT Biopharma posted a Q2 operating loss of $4.5 million, widening from $1.5 million a year earlier.
- Net loss was $4.5 million, narrowing from $30.2 million in the prior-year quarter due to a $28.7 million non-cash Greenshoe Rights liability then.
- R&D expenses climbed to $1.1 million from $0.4 million, driven by higher materials and production costs.
- SG&A expenses rose to $3.4 million from $1.1 million on higher marketing spend, with legal and consulting fees also up.
- Cash and cash equivalents were about $5.1 million at June 30, 2026, seen funding operations through Q4 2026; Phase 1 updates for GTB-3650 and GTB-5550 are expected in 2H 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
